Detail akcie Fluidigm online

Business Summary: Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Standard Biotools Inc revenues increased 9% to $106.3M. Net loss decreased 61% to $74.7M. Revenues reflect Proteomics segment increase of 22% to $63.9M, China segment increase of 40% to $15.8M, United States segment increase of 8% to $44.1M. Lower net loss reflects Loss on forward sale of Series B Preferr decrease from $60.1M (expense) to $0K, Loss on bridge loans decrease from $13.7M (expense) to $0K.